Identification of Small-Molecule Inhibitors Targeting Porphyromonas gingivalis Interspecies Adherence and Determination of Their In Vitro and In Vivo Efficacies

Porphyromonas gingivalis is one of the primary causative agents of periodontal disease and initially colonizes the oral cavity by adhering to commensal streptococci. Adherence requires the interaction of a minor fimbrial protein (Mfa1) of P. gingivalis with streptococcal antigen I/II (AgI/II). Our previous work identified an AgI/II peptide that potently inhibited adherence and significantly reduced P. gingivalis virulence in vivo, suggesting that this interaction represents a potential target for drug discovery. ABSTRACT Porphyromonas gingivalis is one of the primary causative agents of periodontal disease and initially colonizes the oral cavity by adhering to commensal streptococci. Adherence requires the interaction of a minor fimbrial protein (Mfa1) of P. gingivalis with streptococcal antigen I/II (AgI/II). Our previous work identified an AgI/II peptide that potently inhibited adherence and significantly reduced P. gingivalis virulence in vivo, suggesting that this interaction represents a potential target for drug discovery. To develop targeted small-molecule inhibitors of this protein-protein interaction, we performed a virtual screen of the ZINC databases to identify compounds that exhibit structural similarity with the two functional motifs (NITVK and VQDLL) of the AgI/II peptide. Thirty three compounds were tested for in vitro inhibition of P. gingivalis adherence and the three most potent compounds, namely, N7, N17, and V8, were selected for further analysis. The in vivo efficacy of these compounds was evaluated in a murine model of periodontitis. Treatment of mice with each of the compounds significantly reduced maxillary alveolar bone resorption in infected animals. Finally, a series of cytotoxicity tests were performed against human and murine cell lines. Compounds N17 and V8 exhibited no significant cytotoxic activity toward any of the cell lines, whereas compound N7 was cytotoxic at the highest concentrations that were tested (20 and 40 μM). These results identify compounds N17 and V8 as potential lead compounds that will facilitate the design of more potent therapeutic agents that may function to limit or prevent P. gingivalis colonization of the oral cavity.

[1]  J. Trent,et al.  Identification of functional domains of the minor fimbrial antigen involved in the interaction of Porphyromonas gingivalis with oral streptococci , 2020, Molecular oral microbiology.

[2]  D. Ojcius,et al.  Association between periodontal pathogens and systemic disease , 2019, Biomedical journal.

[3]  Jinlian Tan,et al.  ‘Second-generation’ 1,2,3-triazole-based inhibitors of Porphyromonas gingivalis adherence to oral streptococci and biofilm formation , 2019, MedChemComm.

[4]  Jill M. Steinbach-Rankins,et al.  BAR-encapsulated nanoparticles for the inhibition and disruption of Porphyromonas gingivalis–Streptococcus gordonii biofilms , 2018, Journal of Nanobiotechnology.

[5]  Jinlian Tan,et al.  In Vitro and In Vivo Activity of Peptidomimetic Compounds That Target the Periodontal Pathogen Porphyromonas gingivalis , 2018, Antimicrobial Agents and Chemotherapy.

[6]  Jill M. Steinbach-Rankins,et al.  Peptide-modified nanoparticles inhibit formation of Porphyromonas gingivalis biofilms with Streptococcus gordonii , 2017, International journal of nanomedicine.

[7]  Jinlian Tan,et al.  1,2,3-Triazole-based inhibitors of Porphyromonas gingivalis adherence to oral streptococci and biofilm formation. , 2016, Bioorganic & medicinal chemistry.

[8]  S. Jepsen,et al.  Antibiotics/antimicrobials: systemic and local administration in the therapy of mild to moderately advanced periodontitis. , 2016, Periodontology 2000.

[9]  Fadi E El-Rami,et al.  Identification of Small-Molecule Inhibitors against Meso-2, 6-Diaminopimelate Dehydrogenase from Porphyromonas gingivalis , 2015, PloS one.

[10]  John J. Irwin,et al.  ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..

[11]  R. Lamont,et al.  Polymicrobial synergy and dysbiosis in inflammatory disease. , 2015, Trends in molecular medicine.

[12]  D. Graves,et al.  The enduring importance of animal modelsin understanding periodontal disease , 2015, Virulence.

[13]  S. Proudman,et al.  Does periodontal treatment influence clinical and biochemical measures for rheumatoid arthritis? A systematic review and meta-analysis. , 2014, Seminars in arthritis and rheumatism.

[14]  C. Murray,et al.  Global Burden of Severe Periodontitis in 1990-2010 , 2014, Journal of dental research.

[15]  F. Hughes,et al.  The presence, function and regulation of IL-17 and Th17 cells in periodontitis. , 2014, Journal of clinical periodontology.

[16]  R. Lamont,et al.  Breaking bad: Manipulation of the host response by Porphyromonas gingivalis , 2014, European journal of immunology.

[17]  R. Lamont,et al.  Establishment and characterization of a telomerase immortalized human gingival epithelial cell line. , 2013, Journal of periodontal research.

[18]  C. J. Wright,et al.  Microbial interactions in building of communities. , 2013, Molecular oral microbiology.

[19]  R. Lamont,et al.  Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. , 2012, Molecular oral microbiology.

[20]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[21]  John D Lambris,et al.  Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. , 2011, Cell host & microbe.

[22]  Elizabeth A. Novak,et al.  Structural Dissection and In Vivo Effectiveness of a Peptide Inhibitor of Porphyromonas gingivalis Adherence to Streptococcus gordonii , 2010, Infection and Immunity.

[23]  J. Izard,et al.  The Human Oral Microbiome , 2010, Journal of bacteriology.

[24]  Karina Persson,et al.  Two intramolecular isopeptide bonds are identified in the crystal structure of the Streptococcus gordonii SspB C-terminal domain. , 2010, Journal of molecular biology.

[25]  S. Gaffen,et al.  The Interleukin-17 Receptor Plays a Gender-Dependent Role in Host Protection against Porphyromonas gingivalis-Induced Periodontal Bone Loss , 2008, Infection and Immunity.

[26]  R. Lamont,et al.  Interaction of Porphyromonas gingivalis with Oral Streptococci Requires a Motif That Resembles the Eukaryotic Nuclear Receptor Box Protein-Protein Interaction Domain , 2008, Infection and Immunity.

[27]  R. Lamont,et al.  Structural Characterization of Peptide-Mediated Inhibition of Porphyromonas gingivalis Biofilm Formation , 2006, Infection and Immunity.

[28]  S. Amar,et al.  Periodontal disease and systemic conditions: a bidirectional relationship , 2006, Odontology.

[29]  Ajay N. Jain,et al.  Robust ligand-based modeling of the biological targets of known drugs. , 2006, Journal of medicinal chemistry.

[30]  F. Yoshimura,et al.  Short Fimbriae of Porphyromonas gingivalis and Their Role in Coadhesion with Streptococcus gordonii , 2005, Infection and Immunity.

[31]  R. Lamont,et al.  Role of the Streptococcus gordonii SspB protein in the development of Porphyromonas gingivalis biofilms on streptococcal substrates. , 2002, Microbiology.

[32]  S. Socransky,et al.  Microbial complexes in subgingival plaque. , 1998, Journal of clinical periodontology.

[33]  J. Slots,et al.  Attachment of Bacteroides melaninogenicus subsp. asaccharolyticus to Oral Surfaces and Its Possible Role in Colonization of the Mouth and of Periodontal Pockets , 1978, Infection and immunity.

[34]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..